(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 18.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Ginkgo Bioworks Holdings's revenue in 2026 is $180,606,000.On average, 5 Wall Street analysts forecast DNA's revenue for 2026 to be $10,972,282,759, with the lowest DNA revenue forecast at $9,787,743,977, and the highest DNA revenue forecast at $12,300,420,359. On average, 2 Wall Street analysts forecast DNA's revenue for 2027 to be $14,791,284,262, with the lowest DNA revenue forecast at $14,352,005,175, and the highest DNA revenue forecast at $15,377,191,680.
In 2028, DNA is forecast to generate $18,138,287,960 in revenue, with the lowest revenue forecast at $17,599,640,913 and the highest revenue forecast at $18,856,887,957.